• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A Compilation of Spasticity Studies Evaluating Onabotulinumtoxin A (P3.042)
CONCLUSIONS: OnabotulinumtoxinA has been extensively studied for treatment of spasticity against a variety of rating scales/assessments and outcomes measures.Study Sponsored by: Allergan, Inc.Disclosure: Dr. Patel has received personal compensation for activities with Allergan Inc. Dr. Manack has received personal compensation for activities with Allergan Inc.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Patel, P., Manack, A. Tags: Neural Repair and Neuro-rehabilitation: Clinical Source Type: research

OnabotulinumtoxinA in Lower Limb Spasticity: Safety Results from a Pooled Analysis (P03.266)
CONCLUSIONS: OnabotulinumtoxinA treatment in lower limb spasticity was found to be safe and well-tolerated. Majority of AEs were considered not related to onabotulinumtoxinA and treatment-related AEs are consistent with the known mechanism of action of onabotulinumtoxinA.Supported by: Allergan, Inc.Disclosure: Dr. Earl has received personal compensation for activities with Allergan, Inc. as an employee. Dr. Earl holds stock and/or stock options in AGN and GlaxoSmithKline, Inc. Dr. James has received personal compensation for activities with Allergan, Inc as an employee. Dr. Li has received personal compensation for activit...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Earl, N., James, L., Li, H.-I., Shi, G., Demos, G., Dimitrova, R. Tags: P03 Neural Repair Source Type: research

OnabotulinumtoxinA Efficacy in Lower Limb Spasticity: Results of Three Studies (P03.264)
CONCLUSIONS: OnabotulinumtoxinA (300U) significantly decreases ankle flexor tone in adults with post-stroke lower-limb spasticity.Supported by: Allergan, Inc.Disclosure: Dr. Dimitrova has received personal compensation for activities with Allergan, Inc. as an employee. Consulting service from Glaxo-Smith-Kline, Japan.....Financial support from GSK Japan, Eisai Dr. Kaji has received personal compensatino for activities with Glaxo-Smith-Kline, Japan as a consultant. Dr. Kaji has received research support from GSK Japan, Eisai. Dr. Ward has received personal compensation for activities with Allergan Inc. as a participant on a...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Dimitrova, R., Kaji, R., Ward, A., Li, H.-I., Fulford-Smith, A., Earl, N. Tags: P03 Neural Repair Source Type: research